Glasswing Ventures

Glasswing Ventures is a Boston-based early-stage venture capital firm that invests primarily in AI-native and frontier technology startups. The firm focuses on enterprise software, cybersecurity, and related infrastructure rather than developing therapeutics, diagnostics, or healthcare products itself. Founded in 2016, Glasswing positions itself as a "first-capital-in" investor and provides portfolio support through operating expertise, advisory councils, and customer-access networks. The firm is an active private investor and has raised multiple funds, including a Fund III announced in November 2025 with more than $200 million in commitments. While some portfolio companies may serve healthcare or life sciences customers, Glasswing Ventures itself is not a biotech, pharma, or healthcare operating company.